Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Delayed Quote. Delayed  - 10/26 07:03:14 pm
98.34 USD   +0.73%
10/24CELGENE CORPORA : quaterly earnings release
10/24 CELGENE CORPORA : to Webcast at Upcoming Investor Conferences in Nov..
10/20 CELGENE : Oral OTEZLA® ▼ (Apremilast) Receives Positive Nice R..
News SummaryMost relevantAll newsSector news 

Celgene Corporation : Celgene's Profits Fall, But Focus Remains on Pipeline

share with twitter share with LinkedIn share with facebook
share via e-mail
01/24/2013 | 07:47pm CEST

--Celgene's Q4 net falls, while revenues rise

--FDA approval decision for multiple myeloma drug Pomalyst expected in February

--Celgene shares down 2.4% to $97.64 so far this week as investors take profits

(Updates throughout adding details and analyst comment.)

   By Joseph Walker and Melodie Warner 

Celgene Corp.'s (CELG) fourth-quarter earnings fell 36% as restructuring costs and other special items hurt the drug maker's margins and masked its increased revenue.

The results had been expected since the Summit, N.J., company pre-announced full-year results for 2012 and 2013 guidance at an investor meeting earlier this month.

Celgene's revenues jumped 13% to $1.45 billion in the quarter, largely on the strength of its core blood-cancer drug franchise, which includes the blockbuster Revlimid treatment.

However, investor attention has been focused on the company's late-stage product pipeline, which includes what Celgene says are three "potential blockbusters" that would expand the company's portfolio into new disease areas.

The first of those drugs likely to reach the market is Pomalyst, a treatment for the patients with relapsed multiple myeloma, a bone marrow cancer. The U.S. Food and Drug Administration is scheduled to make an approval decision by Feb. 10. Celgene said it would launch the drug shortly after approval.

"Our commercial and medical affairs teams are ready to launch and support the thousands of patients who have exhausted all existing myeloma therapies," Celgene Executive Vice President Mark Alles said. "Successfully launching Pomalyst is a major corporate objective and we are ready."

Celgene shares fell 0.6% to $97.64, and are down 2.4% so far this week as investors take profits. Even with the recent slide, the stock has soared 24% in 2013, as investors have placed a high premium on the company's pipeline.

Celgene also plans to seek FDA approval for apremilast, a treatment for the skin disease Psoriasis, and its cancer drug Abraxane for patients with pancreatic cancer this year. Both drugs are projected to be generate billions of dollars annually for Celgene.

The new drugs are part of Celgene's strategy to expand beyond its core hematology franchise and build out new product lines in cancer to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $263.1 million, or 61 cents a share, down from $410.2 million, or 91 cents, a year earlier. Excluding items such as stock-based compensation, acquisition and restructuring costs, adjusted per-share earnings rose to $1.32 from $1.05 a year ago.

Analysts polled by Thomson Reuters had forecast earnings of $1.31 a share on revenue of $1.46 billion.

Revlimid sales jumped 17% to $1 billion, while Vidaza sales climbed 14% to $216 million.

Gross margin fell to 22.2% from 31.5% as costs rose because of preparations for the launches of Abraxane for non-small-cell lung cancer and Pomalyst. Abraxane received FDA approval for that indication in October.

Write to Joseph Walker at joseph.walker@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
10/24CELGENE CORPORATION : quaterly earnings release
10/24 CELGENE CORPORATION : to Webcast at Upcoming Investor Conferences in November
10/20 CELGENE : to Present New Data on Investigational Compounds at UEGW and ACG Congr..
10/20 CELGENE : Patent Issued for Romidepsin Formulations and Uses (USPTO 9463215)
10/20 CELGENE : Inaugural Chief Medical Officer Joins Pancreatic Cancer Action Network..
10/20 CELGENE : Oral OTEZLA® ▼ (Apremilast) Receives Positive Nice Recommendatio..
10/19 CELGENE : Chesley Taft Associates buys $17,871,151 stake in Celgene Corporation
10/18 CELGENE CORPORATION : and Sage Bionetworks Announce Technology Collaboration to ..
10/18 CELGENE : Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Exte..
More news
Sector news : Bio Therapeutic Drugs
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/21DJU.S. HOT STOCKS : Hot Stocks to Watch
10/20DJALKERMES : Shares Surge
10/20 ACTELION : raises guidance for third time this year on strong PAH sales
10/18 Pfizer to start shipping biosimilar version of J&J's Remicade in November
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
10/24 Biotech Is Difficult Till The Election - Cramer's Lightning Round (10/21/16)
10/22 S&P 500 WEEKLY UPDATE : A Stock Market In No Man's Land Searching For A Near Ter..
10/20 Collaborative Leukemia Trial Orbits Moonshot Initiative
10/20 England's NHS advisor backs Celgene's Otezla
10/19 Celgene Dribbles Out Endoscopy Data At Last
Financials ($)
Sales 2016 11 072 M
EBIT 2016 5 780 M
Net income 2016 3 503 M
Debt 2016 6 835 M
Yield 2016 -
P/E ratio 2016 23,82
P/E ratio 2017 17,12
EV / Sales 2016 7,45x
EV / Sales 2017 6,09x
Capitalization 75 674 M
More Financials
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 138 $
Spread / Average Target 42%
Consensus details
EPS Revisions
More Estimates Revisions
Mark J. Alles Chief Executive Officer & Director
Jacqualyn A. Fouse President, Chief Operating Officer & Director
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.-2.73%118 162
GILEAD SCIENCES, INC.-26.47%98 196
ACTELION LTD3.65%15 587
More Results